AnaptysBio, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California. It focuses on the development of antibody therapeutics targeting immune-mediated inflammatory diseases and cancer.
The company’s platform technology enables the rapid discovery and optimization of fully human antibodies using its proprietary SHM-XEL™ system.
AnaptysBio has a pipeline of wholly-owned programs, including ANB032 for atopic dermatitis, ANB033 for celiac disease, and ANB091 for moderate-to-severe psoriasis.
Official website: anaptysbio.com
To provide comprehensive coverage, we aggregate data and news under the name AnaptysBio, encompassing the following company names, divisions, and related entities:
Anaptys Royalty Co.
This list encompasses current and former names, alternate names, and key divisions associated with AnaptysBio, ensuring you can easily find all relevant information under a single, unified profile.
